Sordillo P P, Helson L, Hajdu S I, Magill G B, Kosloff C, Golbey R B, Beattie E J
Cancer. 1981 May 15;47(10):2503-9. doi: 10.1002/1097-0142(19810515)47:10<2503::aid-cncr2820471033>3.0.co;2-3.
One hundred and sixty-five cases of malignant schwannoma were reviewed. Sixty-five (40%) of the patients had evidence of disseminated neurofibromatosis. Patients with neurofibromatosis were younger, had malignant schwannomas that were centrally rather than peripherally located, and had a shorter five-year survival (23%) than patients with solitary malignant schwannomas (47%). Histologically, tumors developing in patients with neurofibromatosis had a collagenous appearance, while tumors in patients without neurofibromatosis were undifferentiated and highly cellular. The clinical course of both groups of patients tended to be that of multiple local recurrences, although local recurrence had a more ominous prognosis in patients with neurofibromatosis. Chemotherapy responses in all these patients were extremely poor; however, the results of adjuvant therapy after surgery appeared encouraging. Fourteen patients (8.5%) had a malignant schwannoma in an area of prior radiation therapy and died of disease a median of 14 months after diagnosis. Malignant schwannoma should be considered in the differential diagnosis of tumors developing in areas previously treated with radiation.
回顾了165例恶性神经鞘瘤病例。其中65例(40%)患者有播散性神经纤维瘤病的证据。患有神经纤维瘤病的患者更年轻,其恶性神经鞘瘤位于中央而非外周,且其五年生存率(23%)低于孤立性恶性神经鞘瘤患者(47%)。组织学上,神经纤维瘤病患者发生的肿瘤呈胶原样外观,而无神经纤维瘤病患者的肿瘤未分化且细胞高度丰富。两组患者的临床病程往往都是多次局部复发,尽管局部复发在神经纤维瘤病患者中预后更凶险。所有这些患者的化疗反应都极差;然而,手术后辅助治疗的结果似乎令人鼓舞。14例(8.5%)患者在既往放疗区域发生恶性神经鞘瘤,诊断后中位14个月死于疾病。在鉴别诊断既往接受过放疗区域发生的肿瘤时,应考虑恶性神经鞘瘤。